|
||
|
Press ReleaseAccuro Biologics Ltd joins the UniTargetingResearch Clone Consortium through a multi-year service agreement with UniTargetingResearch ASABERDEEN, UK -- May 3, 2007 -- Accuro Biologics Ltd, a privately held biotechnology services company, and UniTargetingResearch AS, a venture backed technology company, announce the execution of a two year service agreement. Under the agreement, Accuro Biologics will provide mammalian cell line development and other services to the UTR Clone Consortium using novel UTR technologies for increasing protein production. The terms of the deal were not disclosed. "This deal represents a further endorsement of the strong technical and commercial capabilities within Accuro Biologics. We look forward to working with UTR in the continued commercialisation of UTR's proprietary technologies, " said Graham Carter, Managing Director of Accuro Biologics. "As part of the UTR Clone Consortium product offer of high performance mammalian clones incorporating novel solutions for improved recombinant protein production, UTR strives to supply the highest possible quality of technology and products to its customers. UTR's agreement with Accuro represents a step towards that end" said Dr. Avinoam Kadouri, UTR's strategic advisor. About Accuro Biologics LtdAccuro Biologics is a specialist research services company serving the pharmaceutical, biotechnology and wider research community to provide access to advanced capabilities in protein and antibody engineering, mammalian cell line engineering and immunogenicity profiling. The company is UK-based and operates from its own fully equipped laboratories within the Aberdeen Science and Technology Park, Aberdeen, Scotland. For more information, please contact: Graham Carter Tel: +44 (0)1224 707337 About UniTargetingResearch ASUniTargetingResearch AS, a spin-out from the University of Bergen, delivers novel solutions to improve production yields of recombinant proteins in mammalian cell systems, particularly those of pharmacological value (Leads and Targets). UTR currently offers unique proprietary genetic targeting elements which upon incorporation lead to enhanced recombinant protein production in mammalian cell systems. Moreover UTR offers novel high performance cell factories consisting of unique high performance cell lines and vector systems. UniTargetingResearch is based in Bergen, on the west coast of Norway. For further information, please contact: Avinoam Kadouri Tel: +41 793014274 Return to Press Releases |
||
Printer Friendly